Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    
    
                         Lexicon Pharmaceuticals, Inc.
                            Selected Financial Data
    
    Consolidated Statements of Operations Data
    (In thousands, except         Three Months Ended       Year Ended
     per share data)                 December 31,          December 31,
                                --------------------  --------------------
                                  2009       2008       2009        2008
                                --------    --------  --------    --------
                                     (unaudited)           (unaudited)
    Revenues:                           
        Collaborative research    $1,292      $4,388    $9,334     $27,177
        Subscription and 
         license fees           
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Pa. , Sept. 17, 2014 BioClinica®, ... and eClinical Solutions, today announced three of its experts ... for Clinical Data Management to be held September ... Nevada . The Company also announced the innovative ... raise overall quality in clinical trials acquired earlier this ...
(Date:9/17/2014)... PA & Rockville, MD (PRWEB) September 17, 2014 ... won a Small Business Innovation Research (SBIR) grant to ... immunotherapy. The award will provide ITI with approximately $255,000 ... Tree nuts, a leading cause of food allergy, affect ... cause of anaphylaxis behind peanut allergy. Tree nut exposure ...
(Date:9/17/2014)... MA (PRWEB) September 17, 2014 Terracon ... version of its TerraPure tank . This addition ... is molded from FDA-compliant linear polyethylene and available in ... pre-installed fittings and ships in two weeks or less. ... features and benefits found in Terracon’s existing TerraPure tank ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia ... quantitative data from a study of the cost and ... the 50 th Annual Meeting of the European ... poster session today, Christian Frois , Ph.D., of ... a series of planned Intarcia-sponsored, retrospective studies to characterize ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... (OTC Bulletin Board: WDSTD ), a development ... an initial $3.25 million funding in conjunction with its ... controlled by Lonza Walkersville ("Lonza Agreement").  Lonza Walkersville is ... of the world,s leading suppliers to the pharmaceutical, healthcare ...
... FutureFuel Corp. (OTC Bulletin Board: FTFL ) filed ... special cash dividend of $0.20 per share. The ... a special cash dividend of U.S. $0.20 per share on ... 2010. The dividend is payable September 30, 2010. ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ... in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Biology Technology:Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville 2Shire plc - Statement re ProAmatine 2Shire plc - Statement re ProAmatine 3Shire plc - Statement re ProAmatine 4Shire plc - Statement re ProAmatine 5Shire plc - Statement re ProAmatine 6
(Date:9/17/2014)... decline, grasses have returned to some once-denuded patches of ... those places seems healthy again, but a new study ... coastal protection remains diminished. , "We,ve got ... back," said ecologist Mark Bertness, professor of biology at ... journal Biological Conservation . "The metric of a ...
(Date:9/17/2014)... faster since the 1960s. The typical development phases of ... accelerated -- by as much as 70 percent. This ... scientists from Technische Universitt Mnchen based on long-term data ... since 1870. Their findings were published recently in ... was a hot topic, with the very survival of ...
(Date:9/17/2014)... new crime unit designed to fight food fraud ... meat being passed off as beef scientists from ... They describe their approach, which represents a vast improvement ... and Food Chemistry . , Hans-Ulrich Humpf and colleagues ... problem. But they also say that adding, for example, ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... lab-made version of a human protein alleviates symptoms of ... be the basis for a new arthritis drug for ... and Infectious Disease (NIAID), part of the National Institutes ... a cell surface receptor, thus blocking transmission of chemical ...
... research with the flatworm, planaria, offers new clues ... The Forsyth Institute have discovered how the worm's ... Forsyth scientists have found that gap-junction (microscopic ... this signaling. This research, led by Dr. Michael ...
... production of a protein called vasostatin may prove a promising ... of print in Gut. , Pancreatic cancer is the fifth ... is extremely difficult to treat. Only 3% of affected patients ... that has remained static for the past three decades. , ...
Cached Biology News:Synthetic Protein Eases Arthritis Symptoms in Mice 2New understanding of regeneration gained by Forsyth scientists 2Jefferson researchers find nanoparticle shows promise in reducing radiation side effects 2
MW5...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
Inquire...
Biology Products: